Orbactiv sales history revenue
WebFeb 22, 2024 · Orbactiv (oritavancin) for injection is an antibiotic used to treat adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram -positive microorganisms: Staphylococcus aureus (including methicillin -susceptible and methicillin-resistant isolates), Streptococcus pyogenes, … WebLast February, a U.S. bankruptcy court gave groups interested in buying the biotech until March 2 to make an offer, with Deerfield Management then in the pole position to snap …
Orbactiv sales history revenue
Did you know?
WebFeb 25, 2024 · ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1,200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg vials. Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin. The U.S. Food and Drug Administration (FDA) and … See more Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It … See more Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as See more Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in … See more In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections (ABSSSI) caused by Gram-positive bacteria. The primary endpoints of … See more • "Oritavancin". Drug Information Portal. U.S. National Library of Medicine. See more
Web2.2 Preparation of ORBACTIV for Intravenous Infusion . ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg … WebORBACTIV® (oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused or suspected to be caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureu s (including methicillin-susceptible [MSSA] and -resistant [MRSA ...
WebORBACTIV infusion in patients with a history of glycopeptide allergy. In the Phase 3 ABSSSI clinical trials, the median onset of hypersensitivity reactions in ORBACTIV-treated patients was 1.2 days and the median duration of these reactions was 2.4 days. [see Adverse Reactions (6.1)] 5.4 . Infusion Related Reactions WebFeb 22, 2024 · Orbactiv IV is a prescription medicine used to treat the symptoms of Acute Bacterial Skin and Skin Structure Infections. Orbactiv IV may be used alone or with other medications. Orbactiv IV belongs to a class of drugs called Glycopeptides. It is not known if Orbactiv IV is safe and effective in children younger than 18 years of age.
WebORBACTIV is contraindicated in patients with known hypersensitivity to ORBACTIV. 5 WARNINGS AND PRECAUTIONS 5.1 Coagulation Test Interference . ORBACTIV has been shown to artificially prolong aPTT for up to 120 hours, PT and INR for up to 12 hours, and activated clotting time (ACT) for up to 24 hours following administration of a
WebORBACTIV® (oritavancin): The first. Single dose. regimen for treating ABSSSI. A single 1200 mg infusion helps ensure adherence to a full course of therapy. * Mild renal impairment creatine clearance (CrCl) 50-79 mL/min, moderate renal impairment CrCl 30-49 mL/min. † Moderate hepatic impairment (Child-Pugh Class B). on screen display 3 downloadWebFeb 1, 2024 · Orbactiv is intended for intravenous infusion, only after reconstitution and dilution. Three Orbactiv 400 mg vials need to be reconstituted and diluted to prepare a … iny terWebOrbactiv (oritavancin) is an antibiotic. It fights against certain bacteria called Gram-positive bacteria. The medication works by preventing the bacteria from making their protective … inys und elmars romaneWebSales Leadership & Product Market Growth - Increased Orbactiv utilization by 270 units in 2016 verses 2015 for an increase of $783k and total Orbactiv sales revenue of $2.1 million;... inys prune cakeon-screen display menu hp laptopWebOrbactiv Sales Medicare Prescription Data PharmaCompass.com. Filters. Reset Filter. Price Info. Product Main Page. U.S. MEDICAID PRESCRIPTIONS. Upload your Marketing & … iny tWebFacilitating access to Orbactiv® (oritavancin) for your patients. 1-844-ORBACTIV (1-844-672-2284) Monday - Friday, 8:00 AM - 8:00 PM ET or email us. Medical Information. For medical inquiries or to report an adverse event, other safety related information, or product complaints for a company product, please contact Medical Information. ... inyss insurance